Skip to content
Medical Health Aged Care

InMode Australia issues warning on counterfeit Morpheus8 devices threatening patient safety.

InMode Australia 2 mins read

InMode Australia, the company behind the award-winning Morpheus8 technology, is warning Australian clinics and patients about the growing risk of counterfeit radiofrequency (RF) microneedling devices being marketed as “Morpheus8.”

Morpheus8, trusted by practitioners worldwide and supported by clinical research, has become a recognised leading technology for skin revitalisation and contouring. However, its success has led to imitation devices that put patient safety and clinic reputations at risk.

 

Counterfeit Devices Pose Serious Safety Concerns

While counterfeit devices may appear visually similar to Morpheus8, they are unregulated, untested, and not listed on the Australian Register of Therapeutic Goods (ARTG). These devices often come from sub-standard facilities and lack the engineered safety features and sterile, single-use microneedling cartridges embedded with RFID chips that define genuine InMode technology.

“The risks are significant,” said Dennis Cronje, Managing Director of InMode Australia. “Counterfeit devices not only compromise treatment outcomes but also expose patients to risks such as burns, scarring, and infection. Clinics using these devices are also operating without insurance coverage and outside regulatory compliance.”

 

Why Authenticity Matters

Only InMode-supplied Morpheus8 devices are ARTG-listed and supported by global clinical trials. Treatments performed by certified InMode providers ensure:

  • Medically engineered devices with patented RF microneedling technology
  • Trained, verified practitioners using sterile, single-use cartridges
  • Consistent, predictable outcomes when performed by trained providers.

“Morpheus8 has earned its global reputation because it delivers results patients can trust, in the hands of providers who are comprehensively trained and supported,” Cronje added. “There is no substitute for authenticity when it comes to medical aesthetics.”

 

InMode’s Action Against Counterfeits

InMode has taken international legal action to combat counterfeit devices, resulting in shutdowns of illegal sellers and the removal of non-approved devices from the market (https://www.prnewswire.com/news-releases/inmode-granted-injunction-against-counterfeit-sales-of-morpheus8-radio-frequency-microneedling-devices-and-needle-cartridges-302446235.html). Locally, InMode Australia continues to monitor for counterfeit activity and urges both clinics and patients to report suspected fakes.

How to Spot a Genuine Morpheus8

Patients/clients are encouraged to protect themselves by looking for a clinic that:

  • Displays the official InMode Verified Provider badge
  • Uses devices with the InMode logo and approved RFID-embedded cartridges
  • Is listed on InMode Australia’s verified provider directory

To learn more, visit https://www.inmode.com.au/blogs/news/the-truth-about-counterfeit-morpheus8-devices-and-how-to-protect-your-skin or email [email protected]


About us:

About InMode Australia

InMode is a leading global provider of innovative aesthetic technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology, light-based applications including IPL and laser, and EMS. InMode strives to enable new emerging non-surgical procedures as well as improving and complimenting existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories including plastic and cosmetic surgery, dermatology, optometry and ophthalmology, gynaecology, women’s health, and cosmetic clinics.


Contact details:

Marton Jakab Head of Marketing - InMode Australia

Phone: (02) 7209 5678 Mobile: 0477 884 773

Email: [email protected]

Website: www.inmode.com.au

Media

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 14/02/2026
  • 06:00
Leukaemia Foundation

International Childhood Cancer Day highlights blood cancer as the biggest cancer threat to Australian children

Blood cancer is the most commonly diagnosed childhood cancer in Australia[i] – and its growing impact is robbing far too many young Australians of…

  • Contains:
  • Medical Health Aged Care
  • 13/02/2026
  • 13:36
Royal Australian College of GPs

RACGP calls on SA Government to ensure evidence-based approach to primary care reforms

The Royal Australian College of GPs (RACGP) has called on the SA Government to match the position laid out by Liberal health spokesperson Heidi Girolamo on the role of pharmacists and GPs in primary care, emphasising the importance of safe, coordinated and evidence-based models that support the best outcomes for South Australians. RACGP SA Chair Dr Sian Goodson said the SA Liberal’s position highlights the need for careful consideration of how different parts of the health system interact. “There is currently no serious evidence base supporting pharmacy prescribing trials, and that lack of rigorous data raises real concerns about patient…

  • Contains:
  • Medical Health Aged Care
  • 13/02/2026
  • 11:02
Royal Australian College of GPs

Convenience can’t come at the cost of safety: RACGP calls for safeguards on WA pharmacy pilot

The Royal Australian College GPs (RACGP) has called for guardrails to protect patient safety, following a WA Government announcement that a further 40 pharmacists will commence training this monthto diagnose and treat Western Australians for a range of conditions as part of the Enhanced Access Community Pharmacy Pilot. RACGP WA Chair Dr Ramya Raman said GPs support innovation, but any reforms must strike the right balance between improving access and ensuring quality patient care. “Patients deserve convenience and safety. We support innovation, but diagnosis, follow-up and continuity aren’t optional extras,” she said. “These safeguards exist for a reason, to catch…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.